Since GR inhibitors in CRPC patients are well tolerated, the use of GR inhibitors would be an acceptable means of enhancing RT efficiency and may potentially be a way to reduce tumor relapse frequencies [77]. The gene discussed is NR3C1; the disease is neoplasm.